The staging of the disease, which is essential for determining the treatment plan, is based on tumour size, lymph node involvement, presence of metastases, and specific biomarkers such as oestrogen receptors, progesterone receptors and the ERBB2 (HER2) receptor (Trayes and Cokenakes 2021). The gene discussed is ERBB2; the disease is neoplasm.